Profile of vildagliptin in type 2 diabetes: Efficacy, safety, and patient acceptability

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 247-257

  Pan, C Y ^a   Wang, X L ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Beijing SL Pharmaceutical Co Ltd   (China)

Author keywords

Dipeptidyl peptidase 4; Efficacy; Incretin hormones; Patient acceptability; Safety; Vildagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PKF 275 055; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; COUGHING; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLUENZA; LIPID BLOOD LEVEL; LIPID STORAGE; LIPOLYSIS; LONG TERM CARE; MEDICATION COMPLIANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATIENT ATTITUDE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RISK REDUCTION; SHORT COURSE THERAPY; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84881606576     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S30071     Document Type: Article

References (90)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the preva-lence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87(1):4-14.
2. Holz GG 4th, Kühtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature. 1993;361(6410):362-365.
3. Freeman JS. The pathophysiologic role of incretins. J Am Osteopath Assoc. 2007;107 Suppl:S6-S9.
4. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. 2004;53 Suppl 3:S190-S196.
5. Ahrén B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl. 2008;159:8-14.
6. Banerjee M, Younis N, Soran H. Vildagliptin in clinical practice: a review of literature. Expert Opin Pharmacother. 2009;10(16):2745-2757.
7. Palalau AI, Tahrani AA, Piya MK, Barnett AH. DPP-4 inhibitors in clinical practice. Postgrad Med. 2009;121(6):70-100.
8. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23(4):479-486.
9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, et al; for American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
10. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2010;70(16):2089-2112.
11. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with mac-rovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-412.
12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
13. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34(12):877-890.
14. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 2011;34 Suppl 1:S11-S61.
15. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9): 602-613.
16. Ji L, LJ, Weng J, et al. China Type 2 Diabetes Treatment Status Survey of Treatment Pattern of Oral Drugs Users (China DiaSTAGE). Berlin: The 48th European Association for the Study of Diabetes; 2012.
17. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med. 2010;123(Suppl 3):S28-S37.
18. Aroda VR, Henry RR, Han J, Huang W, et al. Efficacy of GLP-1 Recep-tor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clin Ther. 2012 Jun;34(6):1247-1258
19. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, random-ized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39(3):218-223.
20. Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10(11):1114-1124.
21. Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*. Diabetes Obes Metab. 2008;10(8):675-682.
22. Foley JE, Bunck MC, Möller-Goede DL, et al. Beta cell function follow-ing 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia. 2011;54(8):1985-1991.
23. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76(1):132-138.
24. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(5):2078-2084.
25. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(4):1236-1243.
26. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res. 2009;41(12):905-909.
27. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25(4):435-441.
28. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30(2):217-223.
29. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. 2007;24(9):955-961.
30. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30(12):3017-3022.
31. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25-33.
32. Migoya EM, MJ, Larson PJ, Tanen MR, et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase. 43rd EASD Annual Meeting, Amsterdam; 2007.
33. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun. 2002;291(5):1302-1308.
34. Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun. 2002;298(5):779-784.
35. D'Alessio DA, Denney AM, Hermiller LM, et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(1):81-88.
36. Dunning BE, Ligueros-Saylan M, D'Alessio DA, et al. Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naïve and metformin-treated patients with type 2 diabetes. Diabetologia. 2006;49(S1):S110.
37. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890-895.
38. Kim NHS, Sung YA, Ahn WC, et al. Efficacy and safety of add-on vildagliptin to metformin in comparison to uptitrating metformin therapy. Diabetes. 2012;61(S1):A297
39. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780-789.
40. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vilda-gliptin vs pioglitazone when added to metformin: a 24-week, random-ized, double-blind study. Diabetes Obes Metab. 2008;10(1):82-90.
41. Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vilda-gliptin and pioglitazone in patients with type 2 diabetes inadequately con-trolled with metformin. Diabetes Obes Metab. 2009;11(6):589-595.
42. Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately con-trolled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. Diabetes Obes Metab. 2009;11(10):978-986.
43. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9(2):166-174.
44. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately con-trolled with a sulphonylurea. Diabetes Obes Metab. 2008;10(11): 1047-1056.
45. Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40(6):427-430.
46. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148-1155.
47. Lukashevich V, Kozlovski P, Foley J, et al. Vildagliptin combined with insulin reduces HbA1c without increasing risk of hypoglycemia and weight gain in patients with type 2 diabetes mellitus. Proceedings from the 72nd ADA Scientific Sessions. Philadelphia, PA, USA; 2012.
48. Duttaroy A, Voelker F, Merriam K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol. 2011;650(2-3):703-707.
49. Akarte AS, Srinivasan BP, Gandhi S. Vildagliptin selectively ame-liorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-Cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. J Diabetes Complications. 2012;26(4):266-274.
50. Sato K, Nakamura A, Shirakawa J, et al. Impact of the dipeptidyl pep-tidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet. Endocrinology. 2012;153(3):1093-1102.
51. Hamamoto S, Kanda Y, Shimoda M, et al. Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes Metab. 2012; 15(2):153-163.
52. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92(4):1249-1255.
53. Pratley RE, Schweizer A, Rosenstock J, et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab. 2008;10(10):931-938.
54. Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28(8):1936-1940.
55. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(5):506-515.
56. Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl pep-tidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care. 2008;31(1):108-113.
57. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31(1):30-35.
58. Avogaro A, Giorda C, Maggini M, et al; for Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007;30(5):1241-1247.
59. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
60. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29(1): 14-25.
61. Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):175-185.
62. Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009;94(3):846-852.
63. Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vilda-gliptin in humans. Diabetes Obes Metab. 2011;13(9):775-783.
64. Terasaki M, Nagashima M, Watanabe T, et al. Effects of PKF275- 055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism. 2012;61(7):974-977.
65. Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol. Epub January 26, 2012.
66. Apaijai N, Pintana H, Chattipakorn SC, Chattipakorn N. Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. Endocrinology. 2012;153(8):3878-3885.
67. Matsui T, Nishino Y, Takeuchi M, Yamagishi S. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res. 2011;63(5): 383-388.
68. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves gly-cemic control in subjects with type 2 diabetes. Horm Metab Res. 2006;38(6):423-428.
69. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vilda-gliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83(2):233-240.
70. Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27(4):362-372.
71. Göke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin mono-therapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40(12):892-895.
72. Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab. 2010;12(8):700-708.
73. Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. The efficacy and safety of vilda-gliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2012;37(4):386-398.
74. Berlie HD, Garwood CL. Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. Ann Pharmacother. 2010;44(4):712-717.
75. Gerstein HC, Miller ME, Genuth S, et al; for ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818-828.
76. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes, Obesity and Metabolism. 2012;14(12): 1061-1072.
77. Bryan J, Crane A, Vila-Carriles WH, Babenko AP, Aguilar-Bryan L. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des. 2005;11(21):2699-2716.
78. Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care. 1984;7(5):491-502.
79. Tan MH, Baksi A, Krahulec B, et al; for GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28(3):544-550.
80. Kahn SE, Haffner SM, Heise MA, et al; for ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
81. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60(12):3103-3109.
82. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications. 2010; 24(2):79-83.
83. Nathan DM, Buse JB, Davidson MB, et al; for American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
84. Becker A, Bos G, de Vegt F et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. Eur Heart J. 2003;24(15):1406-1413.
85. Lee CD, Folsom AR, Pankow JS, Brancati FL; for Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation. 2004;109(7):855-860.
86. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocar-dial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
87. Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic con-trol, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care. 2006;29(5):1016-1023.
88. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildaglip-tin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12(6):485-494.
89. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospec-tive 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):947-951.
90. Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes outcomes. JAMA. 2002;288(4):475-482.